Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
Study Phase: Phase 3
Recruitment Status: Recruiting
Start Date: December 14, 2022
End Date: December 16, 2026
Inclusion Criteria:
- Age 18 to ≤ 85 years
- Lp(a)≥ 200 nmol/L during screening
- History of ASCVD as evidenced by history of either:
- Myocardial infarction (presumed type 1 event due to plaque rupture/erosion) and/or
- Coronary revascularization with percutaneous coronary intervention AND at least 1 additional risk factor.
Exclusion Criteria:
- Severe renal dysfunction
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN), or total bilirubin (TBL) > 2 x ULN during screening
- History of hemorrhagic stroke
- History of major bleeding disorder
- Planned cardiac surgery or arterial revascularization
- Severe heart failure
- Current, recent, or planned lipoprotein apheresis
- Previously received ribonucleic acid therapy specifically targeting Lp(a)
-
Conditions:
- Cardiovascular Diseases
- Atherosclerosis